GlassScriptPhysician profile
Maria Valente
NPI 1902889959
$1,593.31
in general payments reported to CMS, 2019-2025
47 companies · $285 in 2025
The $285 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $162 · 2021: $204 · 2022: $287 · 2023: $147 · 2024: $386 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $797 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.07 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $178.96 | 2019-2025 | |
| Macrogenics, INC. | $93.11 | 2022 | |
| Alexion Pharmaceuticals, INC. | $90.60 | 2019-2024 | Ultomiris |
| Daiichi Sankyo INC. | $85.99 | 2019-2025 | Enhertu, Vanflyta |
| Pfizer INC. | $78.19 | 2022-2025 | |
| Janssen Biotech, INC. | $60.30 | 2024-2025 | Rybrevant, Darzalex, Talvey |
| Genentech USA, INC. | $52.05 | 2020-2025 | Itovebi |
| Agios Pharmaceuticals, INC. | $51.56 | 2024-2025 | Pyrukynd |
| Menarini Silicon Biosystems, INC. | $51.30 | 2024 | |
| Astellas Pharma US INC | $50.99 | 2019-2025 | Xtandi |
| Foundation Medicine, INC. | $49.40 | 2020 | |
| Abbvie INC. | $41.58 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $40.54 | 2019-2024 | Keytruda, Welireg, Reblozyl |
| Genzyme Corporation | $37.98 | 2021-2024 | |
| Gilead Sciences, INC. | $36.81 | 2021-2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Valente listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.